A Phase 1 interventional study of BB-025 and BB-031 in Pharmacodynamics, Pharmacokinetics and Healthy Volunteers, sponsored by Basking Biosciences, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Basking Biosciences, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Stroke with a site in Australia — 22 open to participants now, 29 under way, 11 of them phase 3. Stroke · Australia.
Among the 122 studies in Stroke with a site in Australia, this one is the 88th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 in phase 1, and was the 119th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →22 of the 122 studies in Stroke with a site in Australia are open now. Recruiting first, the newest first:
University of Calgary · Sites in Australia, Canada
Ages 18+
Eli Lilly and Company · Sites in Australia, Argentina, Austria and 35 more countries
Ages 50+
Pharmazz, Inc. · Sites in Australia, United States, Germany and 2 more countries
Ages 18–80
The Florey Institute of Neuroscience and Mental Health · Sites in Australia
Ages 18–55
Transverse Medical, Inc. · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 51 · Phase 4 10
First in 1996; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 569 across the 108 interventional studies, 626 across the 13 observational. Of the 87 that completed or were terminated, 34 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 122 have an industry lead sponsor. The 10 most frequent:
Basking Biosciences, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Basking Biosciences, Inc. has 2 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Stroke with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT06527261University of MelbourneElectronic Capturing of Activities During REhabilitation for Upper Limb After Stroke | 2026-12 |
| NCT06495671University of MelbourneAustralasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke | 2026-12-31 |
| NCT07019493The Florey Institute of Neuroscience and Mental HealthYoung Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke | 2026-12-31 |
| NCT06429332Region SkaneInternational Care Bundle Evaluation in Cerebral Hemorrhage Research | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 122 studies in Stroke with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031. Researchers will compare BB-025 to placebo (a look-alike substance that contains no drug) both on its own and after being given a single dose of BB-031 to assess the use of BB-025 as a reversal agent.
In the first part of the study, participants will receive a single dose of BB-025 or placebo. They will be followed for 28 days to check if they have any symptoms.
In the second part of the study, participants will receive a single dose of BB-031 and then be given either BB-025 or placebo. These participants will also be followed for 28 days to check if they have any symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BB-025, Investigational Drug
Drug: BB-025
Drug: Matched placebo to BB-025 cohorts
Drug: BB-025
Drug: BB-031, Investigational Drug
Drug: BB-031
Reversal agent for BB-031
RNA aptamer
Safety as assessed by adverse events (AEs)
Incidence of treatment-emergent AEs
Time frame: From dosing of study drug to final visit (Day 28)
Pharmacokinetics as measured by BB-025 plasma levels
Plasma concentrations of BB-025 (after single dose of drug)
Time frame: From dosing to 24 hours after dosing
Pharmacokinetics as measured by BB-031 plasma levels
Plasma concentrations of BB-031 (after single dose of drug)
Time frame: From dosing to 24 hours after dosing
Pharmacokinetics as measured by BB-025/BB-031 Complex plasma levels
Plasma concentration of BB-025/BB-031 Complex after a single dose of each drug
Time frame: From dosing of BB-031 through 24 hours after dosing of BB-025
Plasma von Willebrand Factor (vWF) Levels
Level of vWF following administration of study drug
Time frame: From dosing of BB-031 or BB-025 to 24 hours after dosing of BB-025
Platelet Function
Whole blood platelet function closure times
Time frame: From dosing of BB-031 or BB-025 to 24 hours after BB-025 dosing
Plan to share: No — Publication from this study not anticipated to need IPD data to be shared
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Mar 2026, 4 months.
Of 26 industry-sponsored phase 1 interventional studies under Stroke, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 4 months is below that.
Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Basking Biosciences, Inc.